New report highlights lack of access to assistive technology
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
In clinical trials, treatment proved more effective than other therapies evaluated
The new hospital is expected to open by March'24
East Syracuse site to serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
India has the second-largest number of adults with diabetes globally, after China
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Subscribe To Our Newsletter & Stay Updated